INFI - Infinity updates trial data for breast cancer therapy; over 88% achieves cancer reduction

Announcing updated data from its ongoing MARIO-3 clinical study, Infinity Pharmaceuticals (NASDAQ:INFI) said that its combination therapy consisting of eganelisib, for metastatic breast cancer, led 88.6% of patients to show tumor reduction. The Phase 2 trial was designed to evaluate eganelisib in combination with Roche’s (OTCQX:RHHBY) atezolizumab (Tecentriq) and chemotherapy nab-paclitaxel (Abraxane) in frontline metastatic triple-negative breast cancer (TNBC). “Tumor reductions in 88.6% of evaluable patients were associated with a disease control rate of 81.4% in patients with PD-L1 negative tumors who are among the most challenging to treat,” Hatem Soliman, M.D. an investigator of the study, said. As of Oct. 02 data cutoff, 44 patients in the 50-subject study were evaluable with 9.9 months of median duration of follow-up. Out of the evaluable patients, tumor reduction stood at 92.8% and 85.2% among patients with PD-L1 positive tumors (13/14) and PD-L1 negative tumors (22/27), respectively. The disease control rate reached

For further details see:

Infinity updates trial data for breast cancer therapy; over 88% achieves cancer reduction